翻译尚未完成，当前显示原文。
Key PointsExelixis’ cabozantinib, addressing various types of cancer, has driven tremendous growth over the past 10 years.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.
